查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600517

基底细胞癌治疗市场：按类型、给药途径、临床变异和最终用户分类 - 全球预测 2025-2030

Basal Cell Carcinoma Treatment Market by Type (Drug Therapy, Radiation Therapy, Surgery), Route of Administration (Oral, Parenteral), Clinical Variant, End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

基底细胞癌治疗市场2023年估值为64.7亿美元，预计到2024年将达到69.4亿美元，复合年增长率为7.67%，到2030年将达到108.7亿美元。

基底细胞癌（BCC）是最常见的皮肤癌类型，主要影响表皮的基底细胞。 BCC的治疗治疗方法多种多样，包括手术切除、局部药物治疗、放射线治疗、动态、光动力治疗以及刺猬蛋白通路抑制剂等标靶药物药物治疗方法。这些治疗的需求主要是由于紫外线 (UV) 暴露的增加和人口老化导致基底细胞癌的发生率不断增加。这些治疗方法的应用对于皮肤科门诊和医院都至关重要，最终用户包括医疗保健提供者、患者、保险公司等。市场成长的推动因素包括微创治疗方法的进步、公众对皮肤癌认识的提高以及政府卫生倡议推动的对早期检测的重视。此外，远端医疗平台的激增正在增加咨询的可近性并推动市场扩张。然而，潜在的限制包括先进治疗的高成本、与选择性治疗相关的副作用以及来自非专利替代品的竞争压力。需要创新的领域包括研究减少副作用和提高疗效的新治疗配方。人工智慧和机器学习的增强对于皮肤癌的早期检测和个人化治疗建议也有希望。还有机会扩展数位健康监测工具的集成，以促进对患者结果的持续追踪。可能阻碍市场成长的挑战包括监管障碍、新兴市场的报销问题以及熟练的皮肤肿瘤学专家的短缺。公司应专注于与研究机构的策略伙伴关係，并投资于全面的宣传宣传活动，以加强其创新产品平臺。扩大治疗组合和市场覆盖范围的併购可能是有益的，特别是在服务不足的地区。了解快速变化的市场动态需要不断适应和投资尖端研究。

主要市场统计
基准年[2023] 64.7亿美元
预测年份 [2024] 69.4亿美元
预测年份 [2030] 108.7亿美元
复合年增长率（%） 7.67%

市场动态：快速发展的基底细胞癌治疗市场的关键市场洞察

供需的动态交互作用正在改变基底细胞癌治疗市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球基底细胞癌的盛行率
    • 全球对皮肤癌早期诊断和治疗的认识不断增强
  • 市场限制因素
    • 基底细胞癌治疗高成本
  • 市场机会
    • BCC 治疗的进展和改进
    • 远端医疗和远距皮肤病学的新趋势
  • 市场挑战
    • 对严格监管审批的担忧

波特五力：开拓基底细胞癌治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解基底细胞癌治疗市场的外部影响

外部宏观环境因素在塑造基底细胞癌治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解基底细胞癌治疗市场的竞争状况

基底细胞癌治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵基底细胞癌治疗市场供应商绩效评估

FPNV定位矩阵是评估基底细胞癌治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘基底细胞癌治疗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对基底细胞癌治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球基底细胞癌的盛行率
      • 全球对皮肤癌早期诊断和治疗的认识不断提高
    • 抑制因素
      • 基底细胞癌治疗费用高
    • 机会
      • BCC 治疗的进展和改进
      • 远端医疗和远距皮肤病学的新兴趋势
    • 任务
      • 对严格监管核准的担忧
  • 市场区隔分析
    • 治疗类型：高效药物治疗和手术介入以彻底扩大BCC
    • 给药途径：肠胃外给药起效迅速，适合治疗严重的BCC病例。
    • 临床变化：我们专注于改进和提供针对 BCC 的先进治疗方法，以控制硬化性和表面扩散性 BCC 的侵袭性。
    • 最终使用者：政府对医院和诊所设施的扩建和现代化的支持。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章基底细胞癌治疗市场：依类型

  • 药物治疗
    • 免疫疗法
    • 口腔医学
    • 标靶治疗
    • 外用药物
  • 放射治疗
  • 外科手术

第七章基底细胞癌治疗市场：依给药途径

  • 口服
  • 胃肠外的

第八章依临床类型分類的基底细胞癌治疗市场

  • 结节性基底细胞癌
  • 色素性基底细胞癌
  • 硬化性基底细胞癌
  • 表浅扩散性基底细胞癌

第九章基底细胞癌治疗市场：依最终用户分类

  • 居家护理
  • 医院/诊所
  • 专业中心

第10章美洲基底细胞癌治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区基底细胞癌治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲基底细胞癌治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Elekta 推出 Evo，一款革命性的自我调整CT 直线加速器，可增强癌症治疗
    • Medicus Pharma Co., Ltd.透过策略性收购和加强监管策略来推进基底细胞癌治疗
    • Medicus Pharma Ltd. 在非侵入性基底细胞癌治疗方面的创新进展、监管发展和临床研究更新。
    • FDA核准的创新设备增强了基层医疗机构中皮肤癌的早期检测
    • 基底细胞癌非手术治疗方法 VP-315 2 期试验的最终入组和剂量
    • Medison Pharma 与 Regeneron 之间的策略联盟增强了 Ribtayo 在癌症治疗中的全球使用
    • 艾伯维 (AbbVie) 与 Umoja Biopharma 建立策略联盟，透过创新嵌合体抗原受体 (CAR) T 细胞疗法推进肿瘤治疗
    • Medicus Pharma 进行的一项创新性 2 期临床试验针对基底细胞癌的非侵入性治疗。
    • 百时美施贵宝透过策略性收购加强肿瘤产品组合
    • 欧盟核准Ribtayo 治疗进行性肺癌扩大了治疗可能性
  • 战略分析和建议
    • 博士健康公司有限公司
    • 百时美施贵宝公司
    • 再生元製药公司
    • F.霍夫曼拉罗氏股份公司
    • 太阳製药工业有限公司

公司名单

  • AbbVie Inc.
  • Almirall, LLC
  • Amgen Inc.
  • Bausch Health Companies Inc.
  • Biofrontera AG
  • Bristol-Myers Squibb Company
  • Elekta AB
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Galderma SA
  • Glenmark Pharmaceuticals Limited
  • LEO Pharma A/S
  • Medicus Pharma Ltd.
  • Medivir AB
  • OncoBeta GmbH
  • Perrigo Company PLC
  • Redx Pharma PLC
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • SkinCure Oncology
  • Sol-Gel Technologies Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-5C6F41F5B0CA

The Basal Cell Carcinoma Treatment Market was valued at USD 6.47 billion in 2023, expected to reach USD 6.94 billion in 2024, and is projected to grow at a CAGR of 7.67%, to USD 10.87 billion by 2030.

Basal Cell Carcinoma (BCC) is the most prevalent form of skin cancer, primarily affecting the epidermal basal cells. The scope of BCC treatment encompasses a variety of therapies, including surgical excision, topical medications, radiation therapy, cryotherapy, photodynamic therapy, and targeted pharmacological approaches, such as hedgehog pathway inhibitors. The necessity for these treatments stems from the rising incidence of BCC, largely due to increased ultraviolet (UV) exposure and aging populations. Applications of these therapies are crucial in both outpatient dermatology clinics and hospitals, with end-users including healthcare providers, patients, and insurance companies. Market growth is being propelled by advancements in less invasive treatments, increasing public awareness about skin cancer, and greater emphasis on early detection, fueled by governmental health initiatives. Additionally, the surge in telemedicine platforms has enhanced accessibility to consultations, fostering market expansion. However, potential constraints include the high cost of advanced treatments, side effects associated with select therapies, and the competitive pressure from generic alternatives. Areas ripe for innovation include research into novel treatment formulations that offer reduced side effects and improved efficacy. Enhancements in AI and machine learning for early skin cancer detection and personalized treatment recommendations are also promising. An expanding opportunity lies in the integration of digital health monitoring tools to facilitate continuous patient outcomes tracking. Challenges that may impede market growth encompass regulatory hurdles, reimbursement issues in emerging markets, and the limited availability of highly skilled dermatologic oncology professionals. Companies should focus on strategic collaborations with research institutions to bolster innovative product pipelines and invest in comprehensive awareness campaigns. Engaging in mergers and acquisitions to expand treatment portfolios and market reach, particularly in underserved regions, could be beneficial. Understanding the dynamics of this rapidly evolving market necessitates continual adaptation and investment in cutting-edge research.

KEY MARKET STATISTICS
Base Year [2023] USD 6.47 billion
Estimated Year [2024] USD 6.94 billion
Forecast Year [2030] USD 10.87 billion
CAGR (%) 7.67%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Basal Cell Carcinoma Treatment Market

The Basal Cell Carcinoma Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of basal cell carcinoma worldwide
    • Growing awareness regarding early diagnosis and treatment of skin cancer globally
  • Market Restraints
    • High cost of basal cell carcinoma treatment
  • Market Opportunities
    • Advancements and improvements in BCC treatment
    • Emerging trend of telemedicine and teledermatology
  • Market Challenges
    • Concerns associated with stringent regulatory approval

Porter's Five Forces: A Strategic Tool for Navigating the Basal Cell Carcinoma Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Basal Cell Carcinoma Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Basal Cell Carcinoma Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Basal Cell Carcinoma Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Basal Cell Carcinoma Treatment Market

A detailed market share analysis in the Basal Cell Carcinoma Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Basal Cell Carcinoma Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Basal Cell Carcinoma Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Basal Cell Carcinoma Treatment Market

A strategic analysis of the Basal Cell Carcinoma Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Basal Cell Carcinoma Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Almirall, LLC, Amgen Inc., Bausch Health Companies Inc., Biofrontera AG, Bristol-Myers Squibb Company, Elekta AB, Eli Lilly and Company, F. Hoffmann-La Roche AG, Galderma S.A., Glenmark Pharmaceuticals Limited, LEO Pharma A/S, Medicus Pharma Ltd., Medivir AB, OncoBeta GmbH, Perrigo Company PLC, Redx Pharma PLC, Regeneron Pharmaceuticals, Inc., Sanofi S.A., SkinCure Oncology, Sol-Gel Technologies Ltd., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Basal Cell Carcinoma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Drug Therapy, Radiation Therapy, and Surgery. The Drug Therapy is further studied across Immunotherapy, Oral Medications, Targeted Therapy, and Topical Medications.
  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on Clinical Variant, market is studied across Nodular Basal Cell Carcinoma, Pigmented Basal Cell Carcinoma, Sclerosing Basal Cell Carcinoma, and Superficial Spreading Basal Cell Carcinoma.
  • Based on End-Users, market is studied across Homecare, Hospitals & Clinics, and Specialty Centres.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Illinois, Massachusetts, New Jersey, New York, North Carolina, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of basal cell carcinoma worldwide
      • 5.1.1.2. Growing awareness regarding early diagnosis and treatment of skin cancer globally
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of basal cell carcinoma treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements and improvements in BCC treatment
      • 5.1.3.2. Emerging trend of telemedicine and teledermatology
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with stringent regulatory approval
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: High effectiveness of drug therapies and surgery interventions in escalating the BCC completely
    • 5.2.2. Route of Administration: Rapid effect provided by parenteral administration leading to its preference for managing severe BCC cases
    • 5.2.3. Clinical Variant: Focused efforts to improve and provide advanced treatments for sclerosing and superficial spreading BCC to manage its aggressive nature
    • 5.2.4. End-Users: Government support for expanding and modernizing hospital and clinic facilities
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Basal Cell Carcinoma Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Drug Therapy
    • 6.2.1. Immunotherapy
    • 6.2.2. Oral Medications
    • 6.2.3. Targeted Therapy
    • 6.2.4. Topical Medications
  • 6.3. Radiation Therapy
  • 6.4. Surgery

7. Basal Cell Carcinoma Treatment Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral

8. Basal Cell Carcinoma Treatment Market, by Clinical Variant

  • 8.1. Introduction
  • 8.2. Nodular Basal Cell Carcinoma
  • 8.3. Pigmented Basal Cell Carcinoma
  • 8.4. Sclerosing Basal Cell Carcinoma
  • 8.5. Superficial Spreading Basal Cell Carcinoma

9. Basal Cell Carcinoma Treatment Market, by End-Users

  • 9.1. Introduction
  • 9.2. Homecare
  • 9.3. Hospitals & Clinics
  • 9.4. Specialty Centres

10. Americas Basal Cell Carcinoma Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Basal Cell Carcinoma Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Basal Cell Carcinoma Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Elekta Unveils Evo, a Groundbreaking Adaptive CT-Linac for Enhanced Cancer Treatment
    • 13.3.2. Medicus Pharma Ltd. Advances Basal Cell Carcinoma Treatment Through Strategic Acquisitions and Enhanced Regulatory Strategies
    • 13.3.3. Innovative Advances in Non-Invasive Basal Cell Carcinoma Treatment by Medicus Pharma Ltd., Update on Regulatory Development and Clinical Studies
    • 13.3.4. Groundbreaking FDA-Cleared Device Enhances Early Detection of Skin Cancer in Primary Care Settings
    • 13.3.5. Final Enrollment and Dosing in Phase 2 Trial of a Non-Surgical Treatment VP-315 for Basal Cell Carcinoma
    • 13.3.6. Strategic Collaboration Between Medison Pharma and Regeneron to Enhance Global Access to Libtayo for Cancer Treatment
    • 13.3.7. Strategic Collaboration between AbbVie and Umoja Biopharma to Advance Oncology Treatment with Innovative Chimeric Antigen Receptor (CAR) T-cell Therapies
    • 13.3.8. Innovative Phase 2 Clinical Study by Medicus Pharma Targets Non-Invasive Treatment for Basal Cell Carcinoma
    • 13.3.9. Bristol Myers Squibb Enhances Oncology Portfolio Through Strategic Acquisitions
    • 13.3.10. EU Approval of Libtayo for Advanced Lung Cancer Broadens Treatment Horizons
  • 13.4. Strategy Analysis & Recommendation
    • 13.4.1. Bausch Health Companies Inc.
    • 13.4.2. Bristol-Myers Squibb Company
    • 13.4.3. Regeneron Pharmaceuticals, Inc.
    • 13.4.4. F. Hoffmann-La Roche AG
    • 13.4.5. Sun Pharmaceutical Industries Ltd.

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Almirall, LLC
  • 3. Amgen Inc.
  • 4. Bausch Health Companies Inc.
  • 5. Biofrontera AG
  • 6. Bristol-Myers Squibb Company
  • 7. Elekta AB
  • 8. Eli Lilly and Company
  • 9. F. Hoffmann-La Roche AG
  • 10. Galderma S.A.
  • 11. Glenmark Pharmaceuticals Limited
  • 12. LEO Pharma A/S
  • 13. Medicus Pharma Ltd.
  • 14. Medivir AB
  • 15. OncoBeta GmbH
  • 16. Perrigo Company PLC
  • 17. Redx Pharma PLC
  • 18. Regeneron Pharmaceuticals, Inc.
  • 19. Sanofi S.A.
  • 20. SkinCure Oncology
  • 21. Sol-Gel Technologies Ltd.
  • 22. Sun Pharmaceutical Industries Ltd.
  • 23. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. BASAL CELL CARCINOMA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BASAL CELL CARCINOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BASAL CELL CARCINOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BASAL CELL CARCINOMA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BASAL CELL CARCINOMA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TOPICAL MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY NODULAR BASAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY PIGMENTED BASAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SCLEROSING BASAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SUPERFICIAL SPREADING BASAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SPECIALTY CENTRES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 237. BASAL CELL CARCINOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 238. BASAL CELL CARCINOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023